Risk of infectious diseases and cutaneous tumours in solid organ recipients: A meta-analysis of literature

Table 4 Incidence of fungal infections in solid organ transplant recipients n (%)

Ref.	No. of cases/	Age (yr)	M/F	Median follow-	Therapy	Sistemic	Candida spp	Aspergillus spp
	population			up time		infections
Collins et al[45]	158/Liver	46	84/74	NA	Cyclosporine, azathioprine and prednisone	34 (21.5)	28 (17.7)	5 (3.2)
Briegel et al[44]	141/Liver	47 ± 12	79/62	NA	Prednisone, cyclosporine and azathioprine	25 (17.7)	10 (7)	11 (7.8)
Kanj et al[46]	73/Heart-Lung	NA	NA	NA	NA	37 (50.6)	19 (26)	18 (24.6)
Abbott et al[47]	33479/Kidney	43	20154/13325	NA	72.2% with cyclosporine, 65.2% with mycophenolate	595 (1.7)	445 (1.3)	80 (0.2)
Singh et al[39]	130/Liver	NA	NA	NA	tacrolimus	11 (14)	6 (5)	4 (3)
Alangaden et al[66]	127/Kidney	47.1 ± 12.5	76/51	NA	72% tacrolimus	5 (3.9)	5 (3.9)	NA
Pugliese et al[67]	278/Miscellaneous	NA	NA	5.5 ± 5.9 yr	Various	46 (16.5)	45 (16.2)	1 (0.3)
Tessari et al[43]	3293/Miscellaneous	NA	2384/909	NA	NA	22 (0.7)	NA	NA

For each literature study has been indicated number of included patients, type of solid organ transplantation, median age, sex, median follow-up time after solid organ transplantation, type of immunosuppressive treatment and the percentage of patients affected by systemic fungal infections. NA: Data non available in the considered study; M: Male; F: Female.